Shenzhen Hepalink Pharmaceutical Group Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 3,756.34 million compared to CNY 3,111.16 million a year ago. Net income was CNY 511.14 million compared to CNY 338.16 million a year ago.

Basic Earnings Per Share Attributable to Ordinary Equity Holders of the Parent was CNY 0.35 compared to CNY 0.23 a year ago. Diluted Earnings Per Share Attributable to Ordinary Equity Holders of the Parent was CNY 0.35 compared to CNY 0.23 a year ago.